Puma Biotechnology (PBYI) Expected to Post Earnings on Thursday

Key Points

• Puma Biotechnology is expected to report Q3 2026 results after the market closes on November 5, with analysts forecasting earnings of $0.09 per share and revenue of $57.50 million.
• The company exceeded estimates in its latest quarter, reporting $0.19 EPS and $56.5 million in revenue versus forecasts of $0.04 EPS and $53 million, respectively.
• PBYI shares recently opened at $10.62, near their 52-week high, while analysts maintain a “Moderate Buy” consensus with a $6.00 average price target; two directors also sold shares under pre-arranged trading plans.

Puma Biotechnology (NASDAQ:PBYI - Get Free Report) is expected to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Puma Biotechnology to announce earnings of $0.09 per share and revenue of $57.50 million for the quarter. Parties may visit the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported $0.19 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $0.15. Puma Biotechnology had a net margin of 11.50% and a return on equity of 20.76%. The business had revenue of $56.50 million for the quarter, compared to analysts' expectations of $53.00 million. On average, analysts expect Puma Biotechnology to post $0.37 EPS for the current fiscal year and $0.14 EPS for the next fiscal year.

Puma Biotechnology Stock Performance

Shares of NASDAQ PBYI opened at $10.62 on Thursday. Puma Biotechnology has a 1 year low of $4.57 and a 1 year high of $11.50. The stock's 50-day simple moving average is $9.77 and its 200-day simple moving average is $7.86. The firm has a market cap of $548.20 million, a price-to-earnings ratio of 20.42 and a beta of 1.22.

Insider Buying and Selling

In other news, Director Troy Wilson sold 5,000 shares of the firm's stock in a transaction on Monday, September 14th. The stock was sold at an average price of $9.10, for a total value of $45,500.00. Following the completion of the sale, the director directly owned 54,750 shares in the company, valued at approximately $498,225. This trade represents a 8.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Alessandra Cesano sold 62,150 shares of Puma Biotechnology stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $9.12, for a total value of $566,808.00. Following the completion of the transaction, the director directly owned 56,700 shares of the company's stock, valued at $517,104. This represents a 52.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 22.20% of the company's stock.

Analyst Ratings Changes

Several analysts recently weighed in on PBYI shares. TD Cowen boosted their price objective on Puma Biotechnology from $5.00 to $6.00 and gave the company a "hold" rating in a report on Friday, August 7th. Weiss Ratings raised shares of Puma Biotechnology from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Thursday, October 8th. Finally, Wall Street Zen upgraded shares of Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 15th. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $6.00.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company focused on developing and commercializing medicines for the treatment of cancer. The company's lead product is NERLYNX (neratinib), an oral, irreversible tyrosine kinase inhibitor designed to target HER2 and other members of the epidermal growth factor receptor family.

NERLYNX is approved in the United States for the extended adjuvant treatment of adults with early-stage, HER2-positive breast cancer following adjuvant trastuzumab-based therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.